PDE6B

Rod cells convert light into an electrical signal through a chain of chemical steps known as phototransduction. A key part of that chain is an enzyme called cGMP phosphodiesterase, which rapidly breaks down a small signaling molecule such that the rod can respond to light. This enzyme is built from three parts; PDE6B provides the beta subunit. A beta subunit is a specific individual protein chain encoded by a gene that joins with other protein chains to build a larger, functional multi-subunit protein complex. When PDE6B is faulty, the enzyme cannot do its job; cGMP builds-up abnormally and rod cells are gradually damaged and lost. The same gene is known by several other names, including RP40 and CSNB3, and its mouse counterpart is called rd1. This is a widely used laboratory model of retinal degeneration. Because rods are affected first, the earliest symptom is usually trouble seeing in dim light, followed by loss of peripheral vision.

In the people described in the available studies, night blindness typically begins in childhood. Over time, many develope the pattern doctors call rod-cone dystrophy, with progressive narrowing of the peripheral visual field. Eye examinations often show the pigment changes in the retina traditionally described as bone-spicule deposits, along with narrowed retinal vessels. Cataract and cystoid macular edema, a build-up of fluid in the central retina, have both been reported and may affect vision. Importantly, the largest natural-history study to date found that most people had no or only mild loss of central visual acuity, with slowly progressive change over an average of about five years of follow-up. That study and others also found the disease to be highly symmetric between the two eyes, and identified the width of a retinal layer called the ellipsoid zone as a useful measure to track progression. A characteristic ring around the macula is often seen on fundus autofluorescence (definition: An imaging technique that shows natural glow patterns in the retina, which can reveal areas of change or stress in retinal cells.) imaging. Symptoms, age of onset, and speed of progression vary from person to person; no single description fits everyone.

The link between PDE6B and retinitis pigmentosa is well established and appears in standard genetic references. The retinitis pigmentosa form is inherited in an autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) pattern, meaning a person usually has a disease-causing change in both copies of the gene, one from each parent. Many different types of PDE6B-related changes have been reported, including splice-site, missense, nonsense, frameshift, and larger deletions, and new variants continue to be discovered. Although PDE6B is a recognized cause of retinitis pigmentosa, it is a relatively uncommon cause. It's prevalence across populations varies. In some communities with a high rate of marriage between relatives, or where a shared founder variant exists, PDE6B accounts for a larger share of cases. Careful imaging and functional testing have shown consistent, measurable features of PDE6B disease, which researchers see as helpful for planning future treatment studies.

Even people with the same PDE6B variant can have somewhat different severity and progression, and the reasons for this variability are not fully understood. Some individuals carry changes in more than one retinal gene, which can make it harder to predict how PDE6B alone shapes their vision. Most published information comes from single-center studies and case series, so long-term outcomes across diverse populations remain incompletely mapped.

No therapy targeting PDE6B has been approved to date, so current care focuses on monitoring and managing treatable complications. Because the faulty enzyme results from a missing or non-working gene, PDE6B is a natural candidate for gene-replacement approaches that deliver a working copy of the gene to photoreceptors. In the rd10 mouse model, the mouse lacks the working beta subunit; the trial was structured to delivere a human PDE6B gene under the retina; candidates preserved retinal structure and function for up to 15 months. Other laboratory approaches being explored in mouse models include precise gene editing to correct a specific PDE6B change, and strategies that pair a gene with antioxidant protection to improve rescue. Researchers are also studying gene-independent ideas, such as protecting photoreceptors from cell-death pathways and, separately, replacing lost photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) cells, but these remain experimental. These are all animal or laboratory findings, not treatments available to patients, and results in mice or cells do not guarantee the same effect in people.

• Gene-replacement therapy in a PDE6B mouse model

  Preclinical animal study (preprint).

  What was found:

  A single injection under the retina preserved retinal structure and function for up to 15 months, the longest rescue reported in this model.

  Why it matters:

  It supports gene replacement as a plausible future strategy for PDE6B disease.

  Limitation: Animal-only, not yet tested in people, and a preprint that may not be peer-reviewed.

• Prime editing to correct a PDE6B mutation in mice

  Preclinical animal study.

  What was found:

  Editing restored PDE6B protein, protected rod cells, and slowed vision deterioration compared with untreated animals.

  Why it matters:

  It shows a possible path to correcting the underlying DNA change rather than only adding a new gene copy.

  Limitation: Animal-only and targeted to one specific mutation; not an available treatment.

• Largest natural-history study of PDE6B retinal dystrophy

  Observational human cohort study (retrospective).

  What was found:

  Most patients had no or mild central vision loss with slow progression, high symmetry between eyes, a hyperautofluorescent ring, and frequent cystoid macular edema; 43 variants including 16 new ones were identified.

  Why it matters:

  It suggests a wide window during which future treatments might help and points to reliable measures for tracking the disease.

  Limitation: Single referral center and retrospective design may not represent all patients or populations.

• Comparing PDE6A and PDE6B rod-cone dystrophy over time

  Observational human cohort study.

  What was found:

  PDE6B accounted for about 2.4% of the rod-cone dystrophy cohort; visual acuity and visual-field decline over time were similar between the two genes, with many new variants found.

  Why it matters:

  It provides prognostic detail and a basis for designing future therapy studies.

  Limitation: Retrospective, single-country cohort; percentages reflect that specific population.

• Phenotype and genotype of PDE6B retinitis pigmentosa

  Observational human cohort study.

  What was found:

  Most eyes had no visual acuity impairment at first visit, measurements were highly symmetric between eyes, and 43% of the variants were previously unreported.

  Why it matters:

  The mild early impairment and symmetric, measurable features are encouraging for planning clinical trials.

  Limitation: Small number of patients from one center.

Because PDE6B-related retinitis pigmentosa often begins with night blindness in childhood, families may notice a young child having trouble in dim light or unfamiliar dark settings before other symptoms appear. Since the recessive form means both parents typically carry one changed copy, siblings may benefit from genetic counseling to understand their own carrier status, which a specialist can arrange.

• Do my genetic results confirm two disease-causing PDE6B changes, and is my diagnosis the recessive retinitis pigmentosa form or the dominant night-blindness form?
• Given my current test results, what does the typical pace of change look like, and how often should I be monitored?
• Do I have any signs of cataract or cystoid macular edema that could be treated to help my vision?
• Which imaging measures, such as ellipsoid zone width, will you use to follow my retina over time?
• What does my result mean for my children, siblings, and other relatives, and would carrier testing be useful for them?
• Are there natural-history studies or clinical trials relevant to PDE6B that I could learn more about?

Confirming the specific PDE6B variants involved through genetic testing can clarify the diagnosis and inheritance pattern for a family. Because PDE6B disease is often slowly progressive and symmetric, regular monitoring with imaging such as OCT (definition: An imaging test (often abbreviated OCT) that creates a detailed, layer-by-layer picture of the retina without touching the eye.) and autofluorescence can help track any change over time. Treatable complications such as cataract and cystoid macular edema are worth discussing with a retinal specialist, since addressing them has improved vision for some people. A genetic counselor can explain what a recessive result may mean for children, siblings, and other relatives. If you are interested in research studies, RP Hope's Clinical Trials Finder can help screen for options with PDE6B in mind.